Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

Completed · Not applicable

Conditions studied: Gingival Recession, Platelet Derived Growth Factor

In brief

The present randomized clinical trial is aimed at evaluating the efficacy of recombinant human platelet-derived growth factor in combination with collagen matrix for the treatment of multiple adjacent gingival recessions

Key facts

Study ID

NCT04462237

Run by

University of Michigan

People needed

30

Starts

2020-09-09

Expected to finish

2021-08-18

Last updated by the study team

2021-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥ 18 years
• Periodontally and systemically healthy
• Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
• At least two multiple adjacent gingival recessions (with at least one 2 mm or deeper) requiring surgical intervention for root coverage
• No interproximal attachment/bone loss
• No prior experience of root coverage procedures within the last 1 year
• The patient must be able to perform good oral hygiene

You may not qualify if…

• Contraindications for periodontal surgery
• Patients pregnant or attempting to get pregnant (self-reported)
• Untreated periodontitis
• Persistence of uncorrected gingival trauma from traumatic toothbrushing
• Interdental attachment loss greater than 1 mm or furcation involvement in the teeth to be treated
• Presence of severe tooth malposition, rotation or clinically significant super-eruption
• Self-reported current smoking more than 10 cigarettes/day or pipe or cigar smoking
• Allergy to collagen-based medical products

Where it is running

• University of Michigan School of Dentistry — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.